AUROBINDO

April 19, 2017

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Clarification on news item appeared on CNBC TV18 dated 19th April, 2017 captioned 'US FDA Issues 5-6 'Largely Procedural' Observations To Aurobindo Pharma's Unit-III'.

This is with reference to your email dated 19th April, 2017, seeking clarification on the above subject. The United States Food and Drug Administration (US FDA) had conducted an inspection at the Company's Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad from 10th April, 2017 to 18th April, 2017. At the end of the inspection, we have been issued a Form 483 with 6 observations. The observations are all on procedural improvements. None of the observations are related to data integrity. The Company will be responding as per the prescribed time lines.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B ADI REDDY
Company Secretary